Gender Male
Weidong Hao, Ph.D., MBA, CSO, SVP of Operation, a seasoned scientist and executive in Pfizer, MedImmune, AstraZeneca, and Hansoh Bio. He has over 20 years of discovery experience in different therapeutic areas utilizing platforms such as small molecule, antibody, fusion protein, stem cell, AAV. He was the key contributor to AZD3427, which is
currently in phase I clinical trial (NCT04630067). He is the inventor of 5 patents. A graduate of Tsinghua University, Weidong Hao obtained his Ph.D. from SUNY at Stony Brook. He recently played a key role in building up the Biotherapeutics group of Hansoh Bio. He recruited talented scientists and managers and initiated multiple antibody and antibody-drug conjugate projects there.
